Narula N, Wong ECL, AlRamdan R, et al. - This research sought to ascertain the efficacy and safety of higher maintenance dose regimens of adalimumab compared with standard doses in Crohn disease (CD) patients who failed anti-tumor necrosis factor (TNF). CD individuals who failed anti-TNF and received adalimumab were classified according to their post-induction maintenance regimen in this retrospective observational study; 40 mg subcutaneous (sc) weekly or 80 mg sc every other week was defined as a high-dose (HD) maintenance regimen, and 40 mg sc every other week was defined as a standard-dose (SD) maintenance regimen. In this analysis, 40 individuals started on HD regimens following induction, and 77 individuals received the SD regimen. In comparison with SD regimens, high-dose maintenance regimens were correlated with longer time-to-failure n CD patients who failed anti-TNF.